Literature DB >> 17106248

Tissue inhibitor of metalloproteinases-2 improves antitumor efficacy of a replicating adenovirus in vivo.

Myung-hee Kim1, Thomas M Bodenstine, Lucretia A Sumerel, Angel A Rivera, Andrew H Baker, Joanne T Douglas.   

Abstract

Clinical studies of replicating adenoviruses for the treatment of cancer have demonstrated their safety but have yielded disappointing results, indicating the need for new strategies to improve their efficacy. We hypothesized that the efficacy of a replicating adenovirus could be improved by expression of tissue inhibitor of metalloproteinases-2 (TIMP-2), a 21-kDa unglycosylated secretory protein. TIMP-2 specifically inhibits the active forms of a number of matrix metalloproteinases (MMPs) that play a role in the degradation of basement membranes and the extracellular matrix and are therefore involved in the control of the growth, invasion and metastasis of tumor cells, as well as angiogenesis. In addition, TIMP-2 can abrogate tumor growth and angiogenesis by a variety of mechanisms independent of MMP inhibition. In this study, we demonstrate that expression of TIMP-2 enhanced the antitumor efficacy of a replicating adenovirus in vivo, by reducing both tumor growth and angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17106248      PMCID: PMC1797074          DOI: 10.4161/cbt.5.12.3374

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  31 in total

1.  Getting oncolytic virus therapies off the ground.

Authors:  John C Bell; Brian Lichty; David Stojdl
Journal:  Cancer Cell       Date:  2003-07       Impact factor: 31.743

2.  Development of recombinant adenoviruses that drive high level expression of the human metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 and -2 genes: characterization of their infection into rabbit smooth muscle cells and human MCF-7 adenocarcinoma cells.

Authors:  A H Baker; G W Wilkinson; R M Hembry; G Murphy; A C Newby
Journal:  Matrix Biol       Date:  1996-12       Impact factor: 11.583

3.  Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy.

Authors:  N Mittereder; K L March; B C Trapnell
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

4.  Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2.

Authors:  T Yoneda; A Sasaki; C Dunstan; P J Williams; F Bauss; Y A De Clerck; G R Mundy
Journal:  J Clin Invest       Date:  1997-05-15       Impact factor: 14.808

5.  MT1-MMP and MMP-2 mRNA expression in human ovarian tumors: possible implications for the role of desmoplastic fibroblasts.

Authors:  S Afzal; E N Lalani; R Poulsom; A Stubbs; G Rowlinson; H Sato; M Seiki; G W Stamp
Journal:  Hum Pathol       Date:  1998-02       Impact factor: 3.466

6.  Tissue inhibitors of metalloproteinase 2 inhibits endothelial cell migration through increased expression of RECK.

Authors:  Junseo Oh; Dong-Wan Seo; Tere Diaz; Beiyang Wei; Yvona Ward; Jill M Ray; Yoko Morioka; Shuliang Shi; Hitoshi Kitayama; Chiaki Takahashi; Makoto Noda; William G Stetler-Stevenson
Journal:  Cancer Res       Date:  2004-12-15       Impact factor: 12.701

7.  Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer.

Authors:  H Kanayama; K Yokota; Y Kurokawa; Y Murakami; M Nishitani; S Kagawa
Journal:  Cancer       Date:  1998-04-01       Impact factor: 6.860

8.  A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy.

Authors:  S O Freytag; K R Rogulski; D L Paielli; J D Gilbert; J H Kim
Journal:  Hum Gene Ther       Date:  1998-06-10       Impact factor: 5.695

9.  Tumor cell traffic through the extracellular matrix is controlled by the membrane-anchored collagenase MT1-MMP.

Authors:  Farideh Sabeh; Ichiro Ota; Kenn Holmbeck; Henning Birkedal-Hansen; Paul Soloway; Milagros Balbin; Carlos Lopez-Otin; Steven Shapiro; Masaki Inada; Stephen Krane; Edward Allen; Duane Chung; Stephen J Weiss
Journal:  J Cell Biol       Date:  2004-11-22       Impact factor: 10.539

10.  MT1-MMP-dependent neovessel formation within the confines of the three-dimensional extracellular matrix.

Authors:  Tae-Hwa Chun; Farideh Sabeh; Ichiro Ota; Hedwig Murphy; Kevin T McDonagh; Kenn Holmbeck; Henning Birkedal-Hansen; Edward D Allen; Stephen J Weiss
Journal:  J Cell Biol       Date:  2004-11-15       Impact factor: 10.539

View more
  2 in total

1.  Adenoviruses using the cancer marker EphA2 as a receptor in vitro and in vivo by genetic ligand insertion into different capsid scaffolds.

Authors:  Michael Behr; Johanna K Kaufmann; Patrick Ketzer; Sarah Engelhardt; Martin Mück-Häusl; Pamela M Okun; Gabriele Petersen; Frank Neipel; Jessica C Hassel; Anja Ehrhardt; Alexander H Enk; Dirk M Nettelbeck
Journal:  PLoS One       Date:  2014-04-23       Impact factor: 3.240

2.  Radix Tetrastigma hemsleyani flavone inhibits proliferation, migration, and invasion of human lung carcinoma A549 cells.

Authors:  Liangrui Zhong; Junxian Zheng; Qianqian Sun; Kemin Wei; Yijuan Hu
Journal:  Onco Targets Ther       Date:  2016-02-04       Impact factor: 4.147

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.